KR20170043597A - 루카파립의 고 용량 강도 정제 - Google Patents

루카파립의 고 용량 강도 정제 Download PDF

Info

Publication number
KR20170043597A
KR20170043597A KR1020177007284A KR20177007284A KR20170043597A KR 20170043597 A KR20170043597 A KR 20170043597A KR 1020177007284 A KR1020177007284 A KR 1020177007284A KR 20177007284 A KR20177007284 A KR 20177007284A KR 20170043597 A KR20170043597 A KR 20170043597A
Authority
KR
South Korea
Prior art keywords
tablet
camsylate
active ingredient
mammal
tetrahydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020177007284A
Other languages
English (en)
Korean (ko)
Inventor
제프리 에터
Original Assignee
클로비스 온콜로지 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 클로비스 온콜로지 인코포레이티드 filed Critical 클로비스 온콜로지 인코포레이티드
Priority to KR1020237020594A priority Critical patent/KR102803917B1/ko
Publication of KR20170043597A publication Critical patent/KR20170043597A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020177007284A 2014-08-22 2015-08-17 루카파립의 고 용량 강도 정제 Ceased KR20170043597A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237020594A KR102803917B1 (ko) 2014-08-22 2015-08-17 루카파립의 고 용량 강도 정제

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462040849P 2014-08-22 2014-08-22
US62/040,849 2014-08-22
US201562101739P 2015-01-09 2015-01-09
US62/101,739 2015-01-09
PCT/US2015/045522 WO2016028689A1 (en) 2014-08-22 2015-08-17 High dosage strength tablets of rucaparib

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237020594A Division KR102803917B1 (ko) 2014-08-22 2015-08-17 루카파립의 고 용량 강도 정제

Publications (1)

Publication Number Publication Date
KR20170043597A true KR20170043597A (ko) 2017-04-21

Family

ID=55347324

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020177007284A Ceased KR20170043597A (ko) 2014-08-22 2015-08-17 루카파립의 고 용량 강도 정제
KR1020237020594A Active KR102803917B1 (ko) 2014-08-22 2015-08-17 루카파립의 고 용량 강도 정제

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020237020594A Active KR102803917B1 (ko) 2014-08-22 2015-08-17 루카파립의 고 용량 강도 정제

Country Status (23)

Country Link
US (3) US9987285B2 (enExample)
EP (1) EP3182975B1 (enExample)
JP (3) JP6574477B2 (enExample)
KR (2) KR20170043597A (enExample)
CN (2) CN106794185A (enExample)
AU (2) AU2015305696B2 (enExample)
BR (1) BR112017000865A2 (enExample)
CA (1) CA2955495C (enExample)
DK (1) DK3182975T3 (enExample)
ES (1) ES3048688T3 (enExample)
FI (1) FI3182975T3 (enExample)
HR (1) HRP20251484T1 (enExample)
IL (1) IL249946B (enExample)
LT (1) LT3182975T (enExample)
MX (1) MX367260B (enExample)
NZ (1) NZ728392A (enExample)
PL (1) PL3182975T3 (enExample)
PT (1) PT3182975T (enExample)
RS (1) RS67356B1 (enExample)
RU (1) RU2705156C2 (enExample)
SG (1) SG11201700265VA (enExample)
SI (1) SI3182975T1 (enExample)
WO (1) WO2016028689A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12168004B2 (en) 2014-02-05 2024-12-17 Merck Sharp & Dohme Llc Treatment of migraine
HK1232218A1 (zh) 2014-02-05 2018-01-05 Merck Sharp & Dohme Llc Cgrp-活性化合物的片剂制剂
DK3182975T3 (da) * 2014-08-22 2025-10-20 Pharma& Schweiz Gmbh Tabletter med høj doseringsstyrke af rucaparib
CN106008530B (zh) * 2016-07-24 2018-06-26 石家庄久正生物科技有限公司 一种抗卵巢癌药物Rucaparib关键中间体的制备方法
CN108201534A (zh) * 2016-12-16 2018-06-26 苏州苏融生物医药有限公司 一种瑞卡帕布口服缓控释药物组合物及其用途
ES2985767T3 (es) 2017-01-24 2024-11-07 Assia Chem Ind Ltd Formas en estado sólido de rucaparib y de sales de rucaparib
EP3600314A1 (en) 2017-03-27 2020-02-05 Tesaro, Inc. Niraparib compositions
CA3076907A1 (en) 2017-09-26 2019-04-04 Tesaro, Inc. Niraparib formulations
WO2019130229A1 (en) 2017-12-28 2019-07-04 Mylan Laboratories Ltd Methods and intermediates for preparing rucaparib
KR20200121800A (ko) 2018-01-05 2020-10-26 싸이브렉사 1, 인크. 산성 또는 저산소성 질환에 걸린 조직에 관련된 질환의 치료를 위한 화합물, 조성물 및 방법
US12383545B1 (en) 2018-06-08 2025-08-12 Allergan Pharmaceuticals International Limited Treatment of migraine
US12090148B2 (en) 2020-07-29 2024-09-17 Allergan Pharmaceuticals International Limited Treatment of migraine
CN109111454A (zh) * 2018-08-01 2019-01-01 宁波金未生物科技有限公司 一种瑞卡帕布s-樟脑磺酸盐
CN108853030B (zh) * 2018-09-26 2021-10-01 上海朝晖药业有限公司 一种治疗恶性肿瘤的药物制剂及其制备方法
CN111542527A (zh) * 2018-12-06 2020-08-14 上海诚妙医药科技有限公司 芦卡帕利樟脑磺酸盐的新晶型和制备方法及其用途
MY209459A (en) 2019-07-10 2025-07-09 Cybrexa 3 Inc Peptide conjugates of microtubule-targeting agents as therapeutics
CA3146560A1 (en) 2019-07-10 2021-01-14 Cybrexa 2, Inc. Peptide conjugates of cytotoxins as therapeutics
KR20230002487A (ko) 2020-04-28 2023-01-05 리젠 파마슈티컬스 아게 폴리(adp-리보스) 폴리머라제(parp) 억제제로서 유용한 신규 화합물
HRP20251324T1 (hr) 2020-07-14 2025-12-05 Assia Chemical Industries Ltd. Oblici soli rukapariba u krutom stanju
WO2022090938A1 (en) 2020-10-31 2022-05-05 Rhizen Pharmaceuticals Ag Phthalazinone derivatives useful as parp inhibitors
WO2022140537A1 (en) 2020-12-22 2022-06-30 Allergan Pharmaceuticals International Limited Treatment of migraine
BR112023020615A2 (pt) 2021-04-08 2023-12-19 Incozen Therapeutics Pvt Ltd Inibidores de poli(adp-ribose) polimerase
AU2022353124A1 (en) 2021-09-27 2024-04-11 Allergan Pharmaceuticals International Limited Combination comprising atogepant for treating migraine
US11738029B2 (en) * 2021-11-10 2023-08-29 Crititech, Inc. Rucaparib particles and uses thereof
US20250223295A1 (en) 2022-01-11 2025-07-10 Assia Chemical Industries Ltd. Solid state forms of rucaparib tosylate

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20010573B1 (en) 1999-01-11 2006-04-30 Agouron Pharmaceuticals Tricyclic inhibitors of poly(adp-ribose) polymerases
CA2520997A1 (en) 2003-03-31 2004-10-14 Stacie Sara Canan-Koch Salts of tricyclic inhibitors of poly(adp-ribose) polymerases
ATE454893T1 (de) 2003-07-25 2010-01-15 Cancer Rec Tech Ltd Tricyclische parp-hemmer
JP2008513436A (ja) 2004-09-22 2008-05-01 ファイザー・インク ８−フルオロ−２−｛４−［（メチルアミノ）メチル］フェニル｝−１，３，４，５−テトラヒドロ−６ｈ−アゼピノ［５，４，３−ｃｄ］インドール−６−オンのリン酸塩の多形性及び非晶質形態
PL1794163T3 (pl) 2004-09-22 2010-06-30 Pfizer Sposób wytwarzania inhibitorów poli(adp-rybozo)polimerazy
JP2008513435A (ja) 2004-09-22 2008-05-01 ファイザー・インク ポリ（ａｄｐ−リボース）ポリメラーゼ阻害剤を含む治療用組成物
CA2720744A1 (en) * 2008-04-09 2009-10-15 Lek Pharmaceuticals D.D. Granulation of active pharmaceutical ingredients
RS55487B2 (sr) 2010-02-12 2024-06-28 Pfizer Soli i polimorfi 8-fluoro-2-{4-[(metilamino}metil]fenil}-1,3,4,5-tetrahidro-6h-azepino[5,4,3-cd]indol-6-ona
PT2833973T (pt) 2012-04-05 2017-12-21 Vertex Pharma Compostos úteis como inibidores da cinase atr e terapias de combinação dos mesmos
DK3182975T3 (da) 2014-08-22 2025-10-20 Pharma& Schweiz Gmbh Tabletter med høj doseringsstyrke af rucaparib

Also Published As

Publication number Publication date
CA2955495C (en) 2023-09-19
MX2017001540A (es) 2017-05-11
JP6574477B2 (ja) 2019-09-11
EP3182975B1 (en) 2025-10-01
SI3182975T1 (sl) 2025-12-31
ES3048688T3 (en) 2025-12-11
RU2017109139A (ru) 2018-09-24
RS67356B1 (sr) 2025-11-28
US20180200260A1 (en) 2018-07-19
EP3182975A4 (en) 2018-04-18
KR102803917B1 (ko) 2025-05-07
NZ728392A (en) 2023-06-30
AU2015305696B2 (en) 2019-08-29
RU2017109139A3 (enExample) 2019-03-06
CN106794185A (zh) 2017-05-31
PL3182975T3 (pl) 2026-02-23
SG11201700265VA (en) 2017-02-27
LT3182975T (lt) 2025-11-25
JP2020002149A (ja) 2020-01-09
IL249946A0 (en) 2017-03-30
WO2016028689A1 (en) 2016-02-25
US10130636B2 (en) 2018-11-20
CA2955495A1 (en) 2016-02-25
AU2019272064B2 (en) 2021-11-18
MX367260B (es) 2019-08-12
BR112017000865A2 (pt) 2017-12-05
JP2021038242A (ja) 2021-03-11
PT3182975T (pt) 2025-10-28
US20190099430A1 (en) 2019-04-04
AU2019272064A1 (en) 2019-12-19
FI3182975T3 (fi) 2025-11-13
CN113209033A (zh) 2021-08-06
JP7127101B2 (ja) 2022-08-29
EP3182975A1 (en) 2017-06-28
HRP20251484T1 (hr) 2026-01-02
AU2015305696A1 (en) 2017-02-02
DK3182975T3 (da) 2025-10-20
IL249946B (en) 2020-05-31
US20160051561A1 (en) 2016-02-25
JP6797980B2 (ja) 2020-12-09
RU2705156C2 (ru) 2019-11-05
US9987285B2 (en) 2018-06-05
KR20230097211A (ko) 2023-06-30
JP2017525712A (ja) 2017-09-07

Similar Documents

Publication Publication Date Title
KR20170043597A (ko) 루카파립의 고 용량 강도 정제
EP3606511B1 (en) Pharmaceutical composition comprising lenvatinib mesylate
KR20070046172A (ko) 프라미펙솔 또는 약제학적으로 허용되는 이의 염을함유하는 연장 방출성 정제 제형, 이의 제조방법 및 이의용도
JP7639092B2 (ja) 粒状組成物、粒状組成物の製造方法、および粒状組成物の溶出性改善方法
WO2013026553A1 (en) Composition comprising edoxaban
EP3860606B1 (en) Pharmaceutical composition comprising lenvatinib esylate or tosylate
US20060222703A1 (en) Pharmaceutical composition and preparation method thereof
CN106456640A (zh) 色瑞替尼制剂
KR101532810B1 (ko) 당 알콜과 공동 미세화된 엔타카폰의 약학 조성물
JP2002012540A (ja) 水易溶性薬物含有錠剤
US20090215756A1 (en) Formulations containing losartan and/or its salts
HK1232807A1 (en) High dosage strength tablets of rucaparib
HK1232807B (en) High dosage strength tablets of rucaparib
WO2007129522A1 (ja) 乾式製造法製剤
WO2015106960A1 (en) Pharmaceutical composition comprising a combination of a bisphosphonate and cholecalciferol and method for the preparation thereof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20170316

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200814

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220613

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20230118

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20220613

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20230619